, Volume 688, Issue 1, p 10
Date: 05 Oct 2013

Better QOL with etanercept in children with JIA

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Health-related QOL improves significantly after the start of treatment with etanercept in children with juvenile idiopathic arthritis (JIA), according to the results of a study conducted in Germany.

The study, conducted as part of a national observational cohort study, involved 61 randomly selected children (mean age 11 years) with polyarticular JIA who started etanercept treatment between January 2008 and May 2010.* QOL was assessed using the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scales at baseline and at various time points over the 12-month treatment period.

The study showed that QOL in all domains increased significantly in the first 6 months after the start of treatment with etanercept. During the following 6 months of treatment, however, there were no further increases in PedsQL total scores. Nevertheless, QOL remained at a high level, note the researchers, with "some minor fluctuations". Furthermore, the number of patients with inactive disease increased du ...